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The main aim of this study was to investigate the bone-sparing
effect of hesperidin, one of the main flavonoid present in oranges,
in two age groups of ovariectomized female rats, compared with
their intact controls. Young (3 mo) and adult (6 mo) female Wistar
rats were sham operated (SH) or ovariectomized (OVX) and then
pair-fed for 90 days a casein-based diet supplemented or not with
0.5% hesperidin (Hp; n  10/group). In older rats, Hp intake led to
a partial inhibition of OVX-induced bone loss, whereas a complete
inhibition was obtained in younger animals. At both ages, while
plasma osteocalcin concentrations were unchanged, urinary excre-
tion of deoxypyridinoline was reduced by Hp intake, suggesting
that Hp was able to slow down bone resorption. Unexpectedly, in
intact young rats, Hp consumption resulted in a significant increase
in bone mineral density (BMD). Indeed, 6-mo-old HpSH rats had
a similar BMD to 9-mo-old nontreated SH adult rats, suggesting an
accelerated bone mass gain in the young rats. In contrast, in intact
adult rats, Hp did not further increase BMD but did improve their
bone strength. The results of this study show a protective effect of
Hp on bone loss in OVX rats of both ages without uterine
stimulation and accompanied by a lipid-lowering effect. The un-
expected and intriguing findings obtained in intact rats showing
improved BMD in young rats and improved femoral load in adult
rats merit further investigation. The bone and lipid benefits of
hesperidin make it an attractive dietary agent for the management
of the health of postmenopausal women.
bone growth; bone sparing effect; bone mineral density; polyphenols
A NUMBER OF POPULATION-BASED studies support a positive link
between high consumption of fruit and vegetables and im-
proved bone mineral density, an effect postulated to be due to
their acid-base buffering capacity, although not yet proven in
human intervention studies (26). Experimental rodent studies
have shown positive effects on bone with individual polyphe-
nolic components of fruits and vegetables such as quercetin
and rutin (a quercetin glycoside) from onions (15, 24), resvera-
trol from red wine (18), and isoflavones from soy (36) that
inhibit ovariectomy-induced bone loss in rats by inhibition of
bone resorption, independent of the acid-base composition (23,
24). Some human intervention studies with high levels of soy
isoflavones (80–90 mg/day) have shown prevention of bone loss
in postmenopausal women (5, 30), whereas others have not (4,
21). Nevertheless, in practice, consumption of soy products is
relatively low in Western countries compared with the Asian
population, whose average daily intake is 20–40 mg/day (34).
Hesperidin is a monomethoxylated flavanone very abundant
in citrus fruits such as oranges (13) and highly consumed in
Western countries. For example, in Finland, consumption of
hesperidin was estimated to be 28.3 mg/day and contributed to
50% of total intake of flavonoids (17). The structure of hes-
peridin corresponds to hesperetin (4-methoxy-3,5,7-trihy-
droxyflavanone) bound to rutinose (composed of one molecule
of rhamnose and one of glucose) in the C7 position (14).
Hesperetin is absorbed in the colon following release of the
rutinose moiety of hesperidin by the gut microflora (20).
Human bioavailability studies have shown that flavanones
metabolites reached a peak between 5 and 7 h postingestion
(20, 27). In the study of Manach et al. (20), the peak plasma
concentration of hesperetin was found to be close to 1.3 M
following consumption of 1 liter of orange juice, which pro-
vided 450 mg of hesperidin. In the study of Nielsen et al.
(27), in which healthy volunteers consumed hesperetin equiv-
alents supplied as fortified orange juice (corresponding to an
ingested dose of 192  30 mg), the peak plasma concentration
of hesperetin was 1.05  0.25 M.
Hesperetin and metabolites have been shown to exert
several biological activities in preclinical studies, including
antioxidant, anti-inflammatory, analgesic, vasorelaxing, an-
tineoplastic, and lipid-lowering effects (10, 11, 22). In terms
of bone health, hesperidin has been shown to inhibit bone loss in
2-mo-old ovariectomized mice following consumption of 0.5%
hesperidin in the diet (6) and to prevent bone loss in male
orchidectomized rats following citrus juice consumption (8).
In the work presented here, we primarily investigated the
ability of hesperidin to prevent ovariectomy-induced bone loss
in two age groups of female rats (3–6 mo and 6–9 mo). The
effect of this citrus flavanone on the sham-operated counter-
parts was also checked. As a secondary outcome, the lipid
modulating effect of hesperidin was measured due to its rele-
vance to postmenopausal women’s health.
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MATERIALS AND METHODS
Animals and Diets
The study was carried out in accordance with the recommendations
of the Ethical Committee of the French National Institute for Agro-
nomical Research (Institut National de la Recherche Agronomique)
and according to the current legislation on animal experimentation in
France (order no. 87-848 modified in 2001). Two groups of 40 young
3-mo-old (266.2  1.2 g) and adult 6-mo-old (312.5  3.2 g) virgin
female Wistar rats were purchased from INRA (Institut National de la
Recherche Agronomique, Clermont-Ferrand/Theix, France). Half of
the rats in each group were ovariectomized (OVX) and the other half
were sham operated (SH) under anesthesia using chloral hydrate
(Fluka Chemie, Buchs, Switzerland; 80 g/l in saline solution; 0.4
ml/100 g body wt ip). The animals were housed individually in plastic
cages allowing separation and collection of urine and feces at 21°C
with relative humidity of 55% and under a 12:12-h light/dark cycle.
After an adaptation period of 1 wk with a semipurified standard diet
devoid of any soy proteins (which were replaced by casein; INRA,
Jouy-en-Josas, France), the animals were fed the same diet, which
contains 0.4% calcium (Ca) and 0.3% phosporus (P), but supple-
mented or not with hesperidin. Hesperidin (from Sigma, L’Isle
d’Abeau, Chesnes, France) was added to the diet (5 g/kg of diet) of 20
sham-operated (HpSH) and 20 ovariectomized rats (HpOVX; Table 1).
Diets were prepared every week and stored at 4°C. To prevent
hyperphagia induced by castration, the rats were pair-fed. The animals
had free access to water during the entire experiment, and their body
weights and food intake were measured weekly. The daily mean
consumption within each group and during the whole experimental
period (90 days) was 17.9  0.14 g. Urine of each animal was
collected over a 24-h period on day 0 and the day before slaughtering
to measure urinary excretion of deoxypyridinoline (DPD), a marker
for bone resorption (32).
Forty-eight hours before death, the body composition was esti-
mated by dual energy X-ray absorptiometry (DEXA; 33). At nec-
ropsy, on day 90, blood samples were collected into ice-cooled
heparinized plastic tubes containing 200 peptidase inhibitory units of
aprotinin (Iniprol, Choay, Paris, France) per milliliter blood, and
centrifuged immediately (3,500 g for 5 min at 4°C). Then plasmas
were frozen at 20°C until measurements of osteocalcin, a marker of
osteoblastic activity (12). Previously, plasma dedicated to hesperetin
(the aglycone form of hesperidin) detection was acidified with acetic
acid (0.1 M, 1%). Uterine horns were removed and immediately
weighed. Femurs were separated from adjacent tissue, cleaned, and
used for physical measurements (mechanical testing and bone mineral
density).
Physical Analysis
Whole body composition. Rats were anesthetized by intraperitoneal
injection of chloral hydrate (80 g/l in saline solution; 0.4 ml/100 g
body wt). They were scanned with DEXA using Hologic QDR-4500
A (Hologic, Massy, France). Scans were analyzed, and the percentage
of fat and lean masses was measured as previously described (2).
Bone mineral density. Bone mineral density (BMD) was assessed
by DEXA, with the Hologic QDR-4500 A X-ray bone densitometer.
The total right femur BMD (T-BMD), as well as the BMD of two
subregions, one corresponding to the distal femur metaphyseal zone
(M-BMD), rich in cancellous bone, and the other to the diaphyseal
zone (D-BMD), rich in cortical bone, were determined (28). In each
femur scan, distal and proximal metaphyseal regions of interest were
positioned at the same distance from the distal and proximal femur
extremity, respectively, and with the same height. The region of
interest between the two preliminary delimited metaphyseal zones
corresponds to the diaphyseal subregion. Results are given in grams
per square centimeter.
Femoral mechanical testing. Immediately after collection in NaCl
(9 g/l), the length of the right femur and the mean diameter of the
diaphysis were measured using a precision caliper (Mitutoyo, Shropp-
shire, UK). Because of the irregular shape of the femoral diaphysis,
the diameter used in the calculation was the mean of the greatest and
the smallest diaphysis diameters. Femoral failure load was determined
using a three-point bending test. Each bone was secured on the two
lower supports (diameter, 4 mm; separation, 20 mm) of the anvil of a
Universal Testing Machine (Instron 4501; Instron, Canton, MA). An
upper crosshead roller (diameter, 6 mm) was applied in front of the
middle of the shaft of the bone and advanced at 0.5 mm/min. The load
at rupture (Newtons) was automatically determined and recorded by
Instron 4501 software. This test method was previously validated by
using Plexiglas standard probes (38).
Biochemical Analysis
Marker of osteoblastic activity. Osteocalcin (OC) in plasma was
measured by RIA, using rat 125I-labeled OC, goat anti-rat OC anti-
body, and donkey anti-goat second antibody (Biochemical Technol-
ogies kit, Stoughton, MA). The sensitivity was 0.01 nmol/l. The intra-
and interassay precisions were 6.8 and 8.9%, respectively.
Marker of bone resorption. Deoxypyridinoline (DPD) was mea-
sured in urine by competitive RIA (Pyrilinks D kit; Metra Biosystems,
Mountain View, CA). The assay requires a rat monoclonal antibody
against DPD, which is coated to the inner surface of a polystyrene
tube and 125I-labeled DPD. In our experimental conditions, the sen-
sitivity was 2 nmol/l, and the intra- and interassay variation was 4 and
6%, respectively. Results are expressed as nanomoles DPD per
millimole creatinine to take into account interindividual differences of
urine concentration (32). The creatinine assay (kit BioMe´rieux, Marcy
l’Etoile, France) is based on a modified Jaffe´’s method in which picric
acid forms a yellow compound with creatinine presence (7).
Plasma lipids. Plasma total cholesterol and plasma triglycerides
concentrations were enzymatically determined using ready-to-use kits
purchased from BioMe´rieux (Marcy l’Etoile, France). After incuba-
tion with reagents during 10 min at room temperature, the intensity of
the coloration, which is proportional to the cholesterol or triglycerides
content, was measured at 490 nm.
Plasma hesperetin levels. Plasma samples (180 l) were acidified
with acetic acid to pH 4.9 and incubated 5 h at 37°C in the presence
of 1,000 units of -glucuronidase and 45 units of sulphatase (from
helix pomatia, Sigma G0876, L’Isle d’Abeau, Chesnes, France).
Samples were then mixed with 4 volumes of methanol:HCl (200
mmol/l) and centrifuged 5 min at 12,500 g. The supernatant was
analyzed by HPLC. HPLC analysis was performed using a system
consisting of two pumps (model 580, ESA) for high pressure gradient,
a temperature-controlled autosampler (Gilson, Villiers-le-Bel, France), a
1504.6 mm Hypersil BDS C18-5 column (Touzard et Matignon,
Les Ulis, France), a thermostatic chamber and eight-channel Coull-
Array detector (model 5600, Eurosep, Cergy, France). Mobile phases
consisted of a 30 mmol/l NaH3PO4 buffer (pH 3) containing 20%
Table 1. Composition of diets
Control Diet Hesperidin Diet
Casein 15 15
Rapeseed oil 5 5
Wheat starch 74.0 73.5
Calcium phosphate (2H2O) 1.68 1.68
Sodium chloride 0.65 0.65
Potassium citrate 1.14 1.14
Magnesium sulfate 0.5 0.5
Trace elements mix 1 1
Vitamin mix 1 1
Hesperidin — 0.5
Values are shown as g/100 g dry food.
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acetonitrile (A) or 40% acetonitrile (B) (37). Separation was achieved
using a gradient elution (35°C, 0.8 ml/min): 0–3 min, 100% A; 3–30
min, linear gradient from 100% A to 100% B; 30–35 min, 100% B;
35.01–45 min, 100% A. Potentials were set at 50-350-480-550-700-
760-820-850 mV (Pd as reference). Hesperetin was quantified using
the sums of height obtained on the electrodes 2, 3 and 4, 5, 6,
respectively (20).
Statistical Analysis
Results are expressed as means SE. All data were analyzed using
XLSTAT software (Addinsoft, Paris, France). The femoral BMD and
biomechanical variables were subjected to a three-way analysis of
covariance with body weight as the covariate. Other parameters were
analyzed using a three-way ANOVA, testing for any difference
among groups. Thus the main effects assessed were age, dietary
treatment (Hp or control), and operation (SH or OVX). If a result was
found significant (P 	 0.05), the Student-Newman-Keul’s multiple
comparisons test was used to determine the specific differences
between means. Parametric ANOVA was performed when data were
normally distributed with equal variance. If not, nonparametric meth-
ods were selected. Thus a Kruskall-Wallis test was first performed. If
it indicated a significant difference among groups (P 	 0.05), the
Mann-Whitney U test (with Bonferroni adjustment to account for
multiple comparisons) was used to determine specific differences. The
level of significance was set at P 	 0.05 for all statistical tests.
RESULTS
Uterine Weight and Body Composition
The mean uterine weight was lower in all the ovariectomized
groups compared with sham-operated groups (P 	 0.01) at
both ages of rats. Thus accurate ovariectomy was confirmed by
a marked atrophy of uterine horns. In our experimental condi-
tions, uterine weight was unaffected by hesperidin treatment
(Table 2).
The animals continued growing throughout the experimental
period, and the same pattern of body weight evolution was
observed in each age group between day 0 and day 90. At
baseline (D0), 6-mo-old rats had significantly higher body
weight (P 	 0.05) than 3-mo-old animals and this was main-
tained until the end of the study (D90). Despite pair-feeding,
the ovariectomized groups had a significantly (P 	 0.01)
higher body weight than sham-operated groups for both the
young and older rats. Hesperidin treatment did not influence
the body weights of the animals.
As observed for total body weight, the mean percentage of
fat mass measured in the older animals was significantly higher
(P 	 0.01) than in the younger ones and hesperidin consump-
tion had no effect on this parameter (Table 2).
BMD
In the ovariectomized control groups at both ages, ovariec-
tomy induced a significant decrease in total BMD (T-BMD:
5.2%, P 	 0.05 in 6 mo old; 11%, P 	 0.01 in 9 mo old)
as well as in metaphyseal BMD (M-BMD: 6.2%, P 	 0.05
in 6 mo old;13.3%, P	 0.01 in 9 mo old). Diaphyseal BMD
was unaffected by ovariectomy in 6-mo-old animals but was
significantly decreased in 9-mo-old animals (D-BMD for OVX
vs. SH: 6.6%, P 	 0.01; Fig. 1).
Total and metaphyseal bone loss was totally inhibited in
6-mo-old ovariectomized rats fed with hesperidin (HpOVX
vs. OVX: 
14.9% T-BMD, 
10.7% M-BMD; P 	 0.01),
whereas a more partial inhibition was observed in 9-mo-old
rats (HpOVX vs. OVX: 
5.6% T-BMD, 
7.6% M-BMD;
P 	 0.05; Fig. 1, A and B). Diaphyseal BMD, although not
reduced by ovariectomy in 6-mo-old rats, was nevertheless
improved by hesperidin consumption (HpOVX vs. OVX:

12.7%; P	 0.01). Moreover, there appears to be a protection
by hesperidin of D-BMD loss in the 9-mo-old ovariectomized
rats (HpOVX vs. OVX: 
6.9%; P 	 0.01; Fig. 1C).
Unexpectedly, in the sham-operated group of 6-mo-old rats,
BMD was significantly improved at all sites (total, metaphy-
seal, and diaphyseal) by hesperidin consumption (HpSH vs.
SH: T-BMD 
10.6%, M-BMD 
11.5%, D-BMD 
11.8%;
P 	 0.01; Fig. 1).
Bone Size and Ultimate Load
The length (mm) and diameter (mm) of the femur were
similar within groups and between ages of animals (Table 2).
Femoral strength was assessed and reported as femoral
failure load (Table 2). Ovariectomy significantly decreased this
parameter in 9-mo-old control animals (12.9%; P 	 0.05)
but not in 6-mo-old rats. Consumption of hesperidin totally
inhibited the ovariectomy-induced loss of femoral strength in
9-mo-old animals (HpOVX vs. OVX: 
24.3%; P 	 0.01) and
also improved femoral strength in 6-mo-old rats (HpOVX vs.
OVX rats: 
9.9%; P 	 0.05).
In the sham-operated groups, hesperidin consumption sig-
nificantly enhanced femoral strength in 9-mo-old animals
(HpSH vs. SH: 
 23.6%; P 	 0.01), whereas no significant
increases in femoral strength was observed in intact 6-mo-old
animals (Table 2).
Bone Turnover
On day 90, no differences in plasma OC (ng/ml) levels were
observed within 6-mo-old groups with the exception of ovari-
Table 2. Uterine weight, body composition, and femoral ultimate load
6 mo old 9 mo old
SH OVX HpSH HpOVX SH OVX HpSH HpOVX
Uterus wt, mg 1031.982.3 146.69.1a 78767.3 23822.3a 607.121.1 108.63.3a 636.337.2 101.54.5a
Body wt, g 3269b* 3637a* 33515b* 40612a* 40111b 41412a 38212b 4237a
Fat mass, %total body wt 23.21.1† 27.71.6† 25.74.4† 27.71.1† 33.52.2 35.51.6 32.71.9 34.71.6
Length, mm 36.220.36 36.350.31 35.970.30 36.460.30 36.870.27 36.670.27 37.250.26 37.300.20
Diameter, mm 3.580.06 3.480.05 3.610.04 3.710.05 3.740.07 3.570.05 3.780.06 3.800.06
Ultimate load, N 109.53.3* 102.22.9 106.35.3† 112.43.4h* 116.34.3 101.22.9cdg 143.86.7a 125.87.4
Values are means  SE. Uterus weight, body weight, fat mass, femoral length, diameter, and ultimate load measured on day 90 (D90) in 6- and 9 mo-old
animals sham-operated (SH) or ovariectomized (OVX) receiving a standard diet or supplemented with 0.5% hesperidin (HpSH and HpOVX). aP 	 0.01 vs. SH;
bP 	 0.01 vs. OVX; cP 	 0.05 vs. SH; dP 	 0.01 vs. HpSH; gP 	 0.01 vs. HpOVX; hP 	 0.05 vs. OVX. *P 	 0.05 and †P 	 0.01 vs. 9-mo-old rats.
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ectomized rats fed hesperidin where a significantly higher
concentration was measured compared with sham-operated rats
(HpOVX: 38.5  2.6 vs. SH: 25.3  1.9; P 	 0.05). In
9-mo-old animals, ovariectomy enhanced osteocalcin plasma
levels in control rats (OVX: 26.6  2 vs. SH: 18.9  1.1; P 	
0.05) but hesperidin consumption had no effect on this param-
eter (Table 3).
Urinary DPD excretion (Table 3) was increased in ovariec-
tomized control rats in both ages (P 	 0.01). Hesperidin
consumption totally inhibited the ovariectomy-induced in-
crease in DPD excretion in 6-mo-old rats (HpOVX vs. OVX:
38%; P 	 0.01), whereas a partial inhibition was noted in
9-mo-old animals (HpOVX vs. OVX: 18%; P 	 0.05). In
intact animals, hesperidin consumption led to a reduction of
Fig. 1. Total (T-BMD; A), metaphyseal (M-BMD; B), and
diaphyseal (D-BMD; C), femoral density (g/cm2) measured on
day 90 (d90) in 6- and 9-mo-old animals sham-operated (SH)
or ovariectomized (OVX) receiving a standard diet or supple-
mented with 0.5% hesperidin (HpSH and HpOVX). Means 
SE. aP 	 0.01 vs. SH; bP 	 0.01 vs. OVX; cP 	 0.05 vs. SH;
dP 	 0.05 vs. OVX; eP 	 0.01 vs. HpSH; fP 	 0.05 vs.
HpSH; gP 	 0.05 vs. HpOVX; hP 	 0.01 vs. HpOVX. ‡P 	
0.01 vs. 9-mo-old rats.
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urinary DPD levels in 6-mo-old rats (HpSH vs. SH: 16%;
P 	 0.01) but had no effect in 9-mo-old rats.
Plasma Lipids and Hesperetin Concentrations
Plasma total cholesterol and triglycerides concentrations
(Table 3) were significantly lower in the hesperidin-treated
groups compared with the control groups (P 	 0.05) at both
ages.
Finally, the mean plasma concentration of hesperetin was
3.57  0.68 M in all rats consuming hesperidin, while it was
not detectable in plasma of control rats.
DISCUSSION
In the present work, we investigated the effect of hesperidin,
a citrus flavonoid, on bone mineral density and bone metabo-
lism in ovariectomized rats of two ages (3–6 mo and 6–9 mo)
compared with their sham-operated intact counterparts.
Characteristics of the Two Ages of Rats
In the main strains of laboratory rats, sexual maturity is
observed between 4 and 9 mo. Thus we can consider both age
groups of rats as “mature” regarding estrogen status. Accord-
ing to Schapira et al. (35), building of bone mass occurs
throughout the first year of life in Wistar rats with peaks for
parameters of bone formation and mineralization (bone protein
content, alkaline phosphatase activity, BMD, bone calcium
content) mostly attained by age of 8 mo. Thus we can consider
that the younger rats (3–6 mo) still have the capacity to acquire
bone mass (confirmed by comparison of total BMD of sham-
operated rats from 3 to 6 mo, Fig. 1), whereas the older rats
(6–9 mo) have achieved their peak bone mass (no difference in
total BMD of sham-operated animals from 6 to 9 mo, Fig. 1).
As expected, ovariectomy, validated by uterine weight, in-
duced a significant decrease in BMD in rats of both ages.
Similar to what is observed in postmenopausal women, bone
turnover was also increased in ovariectomized rats compared
with sham-operated ones as indicated by a higher urinary DPD
excretion and an increase in plasma levels of osteocalcin (31).
However, comparing the two ages of rats, ovariectomy-
induced osteopenia was more severe in the 6- to 9-mo-old rats
than in young 3- to 6-mo-old rats, leading to greater loss of
trabecular and cortical bone density as well as femoral bone
strength and higher bone turnover in accordance with previ-
ously reported results in growing (15) and adult (29) animals.
Indeed, the younger rats were remarkably insensitive to
changes in bone strength by ovariectomy (Table 2). These
results may be explained by the fact that the diaphyseal BMD
and femoral failure load are related to the cortical compartment
that mainly fulfils mechanical functions and is thus less sensi-
tive to estrogen deficiency than cancellous bone, especially in
the growing skeleton (31). Hence, the 6- to 9-mo-old adult rats
being highly sensitive to ovariectomy-induced osteopenia with
effects on BMD, bone resorption biomarkers, and bone
strength may indeed be the better model for postmenopausal
bone loss (3).
In terms of body composition changes, although ovariecto-
mized rats showed a higher body weight than intact rats, no
difference in fat mass content was observed within animals
between both age groups by the end of the 90-day feeding
period. Moreover, the differences in body weight and fat mass
between young and adult rats at the beginning of the experi-
ment remained stable after 3 mo of treatment, suggesting a
normal evolution of both body weight and composition.
Effect of Hesperidin on Two Ages of Ovariectomized Rats
Hesperidin intake led to a complete inhibition of ovariec-
tomy-induced bone loss in the younger rats and a partial
inhibition in the older rats, where the osteopenia was more
severe. In accordance with the BMD results, ovariectomy
induced a higher urinary excretion of DPD, compared with
values obtained for sham-operated animals. This effect was
inhibited by intake of hesperidin in both age groups of rats
(Table 3). These results suggest that hesperidin protects against
ovariectomy-induced osteopenia, at least in part due to inhibi-
tion of bone resorption. Consistent with these results, a previ-
ous study by Chiba et al. (6) showed that in 2-mo-old ovari-
ectomized mice fed 0.5% hesperidin (same dose as our study)
for 2 mo, trabecular bone loss and thickness were reduced
(compared with sham-operated animals) at the femoral me-
taphysis accompanied by a reduction in the number of oste-
oclasts. Similarly, Deyhim et al. (8) showed that citrus juice
consumption prevented bone loss in male orchidectomized rats
accompanied by a decrease in urinary excretion of hydroxypro-
line, this being consistent with decreased DPD urinary excre-
tion observed in our study and an overall antiresorptive effect.
In terms of bone strength, the older rats were considerably
more sensitive than the younger rats to ovariectomy-induced
reduced bone strength and hesperidin was able to reverse this
loss of strength (Table 2). In the younger rats, ovariectomy did
not significantly affect the cortical bone density, i.e., the
diaphyseal BMD, nor the femoral bone strength. Yet, surpris-
ingly, hesperidin intake led to a significant increase in femoral
load in the HpOVX animals but not in the HpSH animals
(Table 2). Taken together, these results indicate that hesperidin
primarily affected BMD in young intact rats with an effect on
strength (femoral load) only in ovariectomized animals despite
Table 3. Plasma osteocalcin, urinary deoxypyridinoline creatinin, total cholesterol, and triglycerides concentrations
6 mo old 9 mo old
SH OVX Hp SH Hp OVX SH OVX Hp SH Hp OVX
OC, ng/ml 25.31.9* 33.12.8* 32.63.7* 38.52.6c* 18.91 26.62c 22.52.6 29.91.7c
DPD, nmol/mmol creatinin 121.88.8* 164.913.4a* 69.97.9ab* 1027.3b* 54.93.3b 103.311.5 54.74.7b 88.84.5ch
TC, g/l 0.640.11 0.760.04 0.530.09c 0.640.07b 0.680.12 0.770.08 0.600.11c 0.690.09h
TG, g/l 2.311.14 1.770.99 1.360.43c 1.240.37h 2.640.75 1.670.61 1.470.43a 1.230.36h
Values are means  SE. Plasma osteocalcin (OC, ng/ml), urinary deoxypyridinoline (DPD, nmol DPD/mmol creatinin), total cholesterol (TC, g/l), and
triglycerides (TG, g/l) concentrations measured on day 90 in 6- and 9-mo-old SH, OVX, HpSH, and HpOVX animals. aP 	 0.01 vs. SH; bP 	 0.01 vs. OVX;
cP 	 0.05 vs. SH; hP 	 0.05 vs. OVX. *P 	 0.01 vs. 9-mo-old rats.
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the fact that ovariectomy itself did not result in a lower femoral
load. Assuming that effects on strength are linked to changes in
the bone microarchitecture, then ovariectomy may have fra-
gilized the bones of the younger rats in some way that was not
reflected by the femoral load test and that hesperidin intake was
able to counteract the effect of ovariectomy such that an
improved femoral load was observed in the HpOVX animals.
Effect of Hesperidin in Intact Rats
Unexpectedly, hesperidin intake led to a significant increase
in BMD at all three regions in the sham-operated younger rats
(Fig. 1). Furthermore, urinary DPD excretion was significantly
reduced by hesperidin consumption in the sham-operated rats,
indicating a suppression of bone resorption. Whether hesperi-
din also stimulated bone metabolism in the sham-operated rats
contributing to the improved BMD will require further mech-
anistic studies. Interestingly, hesperidin intake seemed to ac-
celerate achievement of peak bone mass in the younger animals
since 6-mo-old HpSH animals had the same peak bone mass as
9-mo-old sham-operated rats (Fig. 1). No further increase in
BMD was seen between 6- and 9-mo-old HpSH animals (Fig.
1). Indeed, in the older sham-operated rats (which had already
achieved peak bone mass), hesperidin did not improve BMD
but did improve strength, once again suggesting an effect of
hesperidin on the bone microarchitecture. All together, these
surprising effects of hesperidin on improved BMD in young
intact rats and improved bone strength in older intact rats
require further investigation with more detailed biochemical
and histomorphometric analyses.
Potential Mode of Action of Hesperidin
Although the molecular action of hesperetin on bone cells is
not yet known, some insights into its mode of action are
emerging with respect to its action on modulation of central
cellular signaling pathways linked to its antioxidant and anti-
inflammatory properties. An important study by Kim et al. (16)
showed that hesperetin fed to 6- and 24-mo-old rats modulated
nuclear factor (NF)-B in their kidneys, a finding that sheds
light on the possible antiresorptive action of hesperetin since
NF-B is also a key signaling factor in osteoclast proliferation
and differentiation (1). Indeed, Kim et al. found that hesperetin
suppressed NF-B signaling through four signal transduction
pathways, NIK/IKK, ERK, p38, and JNK and further showed
effects on the redox regulating transcription factors Trx/Ref-1.
These results would implicate hesperetin as an overall antiag-
ing agent, acting on many tissues, including antiresorptive
effects in bone cells.
Concerning the surprising effect we observed on intact rats
(improved BMD in younger rats, improved ultimate load in
older rats), we can only speculate at this point on a potential
stimulation of bone metabolism by hesperidin. One possibility
is that there is a relationship with the lipid-lowering effects of
hesperidin [see Table 3 for confirmation of lowering of cho-
lesterol and triglycerides levels in our study, in accordance
with previous findings (6, 9)]. It has been shown that statins not
only inhibit cholesterol synthesis but also stimulate bone for-
mation via induction of bone morphogenic protein (BMP-2)
(25). Whether hesperidin stimulates bone formation in this way
remains to be proven. However, in support of an effect on bone
formation, we have preliminary data in osteoblast cells show-
ing stimulation of alkaline phosphatase activity after 12 days of
culture with 4 M of hesperetin (data not shown), indicative of
an effect on osteoblast differentiation as previously shown with
simvastatin, on MC3T3-E1 cells (19).
Conclusions and Perspectives
Taken together, the results of this study show a clear pro-
tective effect of hesperidin on bone loss and strength in
ovariectomized rats of two ages without uterine stimulation.
The older rats were more sensitive to the ovariectomy-induced
bone loss than the younger ones and the main effect of
hesperidin was a slowing down of bone resorption. Surpris-
ingly, hesperidin also stimulated in one hand BMD in young
intact rats and in the other hand femoral strength in older intact
rats that had probably already achieved their peak bone mass at
the start of the feeding period (35). Although the mode of
action of hesperidin is not yet elucidated, our results are
consistent with an antiresorptive effect of hesperetin possibly
via altered NF-B signaling in osteoclast cells. The lipid-
lowering effect of hesperidin was confirmed, but whether this
has any link to a statin-like effect and associated stimulation of
BMP-2 and induced bone formation will require further inves-
tigation.
The identification of a non-hormonal dietary agent that may
help prevent bone loss and stabilize blood lipids opens up
perspectives for the dietary management of women’s health in
relation to menopause or osteopenia, particularly for those
women who are not yet on osteoporotic drug treatment. Fur-
thermore, the broader antiaging potential of hesperidin is of
interest to explore for further health benefits. Detailed mecha-
nistic studies will help to direct the primary organ and target
population in the future that would benefit most from hesper-
idin.
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